Skip to main content
Equibles

FRX · Fennec Pharmaceuticals Inc. · Webcasts, Transcripts & Audio

Use FRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research FRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
13.2900 CAD -1.1700 (-8.09%) At close · Nov 5 Intraday price with Plus
Rebalance outlook locked

Fennec Pharmaceuticals Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Fennec Pharmaceuticals Inc. (FRX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Embed Fennec Pharmaceuticals Inc. earnings calls on your site

Pick a widget, match your page, then paste the code where it should appear.

Widget
Theme
Accent color Pro

Match your site's colors with Pro. The Equibles credit stays on every plan.

Embed code 

                    
The widget credits Equibles and keeps the link below it on every plan.

                

            


            

                Preview
                
            

        

        
    

    




    


    
    

        

            
            
            
            
        

            

                
                    
                    
                    
                    
            

        
        
    


    
    

            
                
                

                
                

                    

                        
                        Conference
                    

                        
Investor event

                    
2026-09-15

                


                
                

                    
Fennec Pharmaceuticals Inc. (FRX) September 15, 2026 Conference Transcript

                    

                    

                


                
                

                        No reported result — non-financial event
                


                
                

                    Audio
                    Transcript
                    Slides
                


                
            
            
                
                

                
                

                    

                        
                        Conference
                    

                        
Investor event

                    
2026-09-15

                


                
                

                    
Fennec Pharmaceuticals Inc. (FRX) September 15, 2026 Conference Transcript

                    

                    

                


                
                

                        No reported result — non-financial event
                


                
                

                    Audio
                    Transcript
                    Slides
                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY26 · Q2

                    
2026-08-11

                


                
                

                    
Fennec Pharmaceuticals Inc. (FRX) Q2 2026 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                Investigator-sponsored studies (ISTs) and label expansion
                                Commercial growth and demand momentum
                                Japan / Asia-Pacific partnership and launch planning
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$17.87M

▲ 85.2% YoY                                

                                

                                    
Diluted EPS

                                    
$0.05

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Conference
                    

                        
Investor event

                    
2026-05-19

                


                
                

                    
Fennec Pharmaceuticals Inc. (FRX) May 19, 2026 Conference Transcript

                    

                    

                


                
                

                        No reported result — non-financial event
                


                
                

                    Audio
                    Transcript
                    Slides
                


                
            
            
                
                

                
                

                    

                        
                        Conference
                    

                        
Investor event

                    
2026-05-19

                


                
                

                    
Fennec Pharmaceuticals Inc. (FRX) May 19, 2026 Conference Transcript

                    

                    

                


                
                

                        No reported result — non-financial event
                


                
                

                    Audio
                    Transcript
                    Slides
                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY26 · Q1

                    
2026-05-14

                


                
                

                    
Fennec Pharmaceuticals Inc. (FRX) Q1 2026 Earnings Call Transcript

                    

                    

                


                
                

                        

                                

                                    
Revenue

                                    
$15.11M

▲ 72.6% YoY                                

                                

                                    
Diluted EPS

                                    
$0.01

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY25 · Q4

                    
2026-03-24

                


                
                

                    
Fennec Pharmaceuticals Inc. (FRX) Q4 2025 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                Pedmark label and lifecycle
                                Label expansion opportunities
                                Financial performance and outlook
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$13.78M*

▲ 73.8% YoY                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-K                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY25 · Q2

                    
2025-08-14

                


                
                

                    
Fennec Pharmaceuticals Inc. (FRX) Q2 2025 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                Revenue Growth and Commercial Performance
                                PEDMARK Adoption and Standard of Care
                                International Expansion via Norgine
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$9.65M

▲ 32.9% YoY                                

                                

                                    
Diluted EPS

                                    
$-0.11

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY25 · Q1

                    
2025-05-13

                


                
                

                    
Fennec Pharmaceuticals Inc. (FRX) Q1 2025 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                AYA (adolescent and young adult) market expansion
                                European launch via Norgine partnership (PEDMARQSI)
                                Fennec HEARS patient support program
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$8.75M

▼ 65.5% YoY                                

                                

                                    
Diluted EPS

                                    
$-0.04

▼ 109.8% YoY                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY24 · Q4

                    
2025-03-10

                


                
                

                    
Fennec Pharmaceuticals Inc. (FRX) Q4 2024 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                AYA market expansion
                                European launch via Norgine
                                NCCN compendia and guidelines
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$7.92M*

▼ 18.6% YoY                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-K                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY24 · Q3

                    
2024-11-07

                


                
                

                    
Fennec Pharmaceuticals Inc. (FRX) Q3 2024 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                PEDMARK commercial execution and five strategic pillars
                                AYA (Adolescent and Young Adult) market expansion
                                Pediatric and academic center adoption vs. compounding
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$6.97M

▲ 7% YoY                                

                                

                                    
Diluted EPS

                                    
$-0.21

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY24 · Q2

                    
2024-08-13

                


                
                

                    
Fennec Pharmaceuticals Inc. (FRX) Q2 2024 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                PEDMARK commercial launch
                                Norgine partnership (PEDMARQSI ex-U.S.)
                                Leadership transition / new CEO
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$7.26M

▲ 118.4% YoY                                

                                

                                    
Diluted EPS

                                    
$-0.20

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY24 · Q1

                    
2024-05-14

                


                
                

                    
Fennec Pharmaceuticals Inc. (FRX) Q1 2024 Earnings Call Transcript

                    

                            
                                Positive tone
                            
                                PEDMARK U.S. commercial launch challenges
                                Norgine ex-U.S. licensing partnership
                                FDA safety communication on substitution
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$25.38M

▲ 1413.2% YoY                                

                                

                                    
Diluted EPS

                                    
$0.41

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY23 · Q4

                    
2024-03-21

                


                
                

                    
Fennec Pharmaceuticals Inc. (FRX) Q4 2023 Earnings Call Transcript

                    

                            
                                Confident tone
                            
                                PEDMARK US commercial launch
                                Norgine licensing deal for Europe
                                FDA communication on sodium thiosulfate substitutions
                    

                


                
                

                        

                                

                                    
Revenue

                                    
$9.73M*

                                

                                

                                    
Gross margin

                                    
93.0%

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-K                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY23 · Q3

                    
2023-11-06

                


                
                

                    
Fennec Pharmaceuticals Inc. (FRX) Q3 2023 Earnings Call Transcript

                    

                    

                


                
                

                        

                                

                                    
Revenue

                                    
$6.51M

                                

                                

                                    
Diluted EPS

                                    
$-0.07

                                

                                

                                    
Gross margin

                                    
94.9%

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY23 · Q2

                    
2023-08-03

                


                
                

                    
Fennec Pharmaceuticals Inc. (FRX) Q2 2023 Earnings Call Transcript

                    

                    

                


                
                

                        

                                

                                    
Revenue

                                    
$3.33M

                                

                                

                                    
Diluted EPS

                                    
$-0.21

                                

                                

                                    
Gross margin

                                    
95.5%

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
            
                
                

                
                

                    

                        
                        Earnings call
                    

                        
FY23 · Q1

                    
2023-05-11

                


                
                

                    
Fennec Pharmaceuticals Inc. (FRX) Q1 2023 Earnings Call Transcript

                    

                    

                


                
                

                        

                                

                                    
Revenue

                                    
$1.68M

                                

                                

                                    
Diluted EPS

                                    
$-0.23

                                

                                

                                    
Gross margin

                                    
94.3%

                                

                                

                                    Rev · 8q
                                    Trailing quarterly revenue
                                

                        

                


                
                

                    Audio
                    Transcript
                    Slides
8-K10-Q                


                
            
    

    

        
Showing 1–17 of 17 webcasts